115 related articles for article (PubMed ID: 11392536)
41. Inhibitors of the sphingomyelin cycle: Sphingomyelin synthases and sphingomyelinases.
Adada M; Luberto C; Canals D
Chem Phys Lipids; 2016 May; 197():45-59. PubMed ID: 26200918
[TBL] [Abstract][Full Text] [Related]
42. Potent inhibition of acid sphingomyelinase by phosphoinositide analogues.
Roth AG; Redmer S; Arenz C
Chembiochem; 2009 Sep; 10(14):2367-74. PubMed ID: 19688786
[TBL] [Abstract][Full Text] [Related]
43. Holotoxin A₁ Induces Apoptosis by Activating Acid Sphingomyelinase and Neutral Sphingomyelinase in K562 and Human Primary Leukemia Cells.
Yun SH; Sim EH; Han SH; Han JY; Kim SH; Silchenko AS; Stonik VA; Park JI
Mar Drugs; 2018 Apr; 16(4):. PubMed ID: 29642569
[TBL] [Abstract][Full Text] [Related]
44. Functional inhibitors of acid sphingomyelinase (FIASMAs).
Kornhuber J; Tripal P; Gulbins E; Muehlbacher M
Handb Exp Pharmacol; 2013; (215):169-86. PubMed ID: 23579455
[TBL] [Abstract][Full Text] [Related]
45. Novel inhibitor of bacterial sphingomyelinase, SMY-540, developed based on three-dimensional structure analysis.
Oda M; Imagawa H; Kato R; Yabiku K; Yoshikawa T; Takemoto T; Takahashi H; Yamamoto H; Nishizawa M; Sakurai J; Nagahama M
J Enzyme Inhib Med Chem; 2014 Jun; 29(3):303-10. PubMed ID: 23488740
[TBL] [Abstract][Full Text] [Related]
46. [The influence of tumor necrosis factor alpha on the processes of sphingomyelin cycle and lipid peroxidation in brain].
Gutner UA; Dudnik LB; Korobko VG; Alesenko AV
Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(4):48-54. PubMed ID: 15875943
[TBL] [Abstract][Full Text] [Related]
47. Neutral sphingomyelinase 2 inhibitors based on the 4-(1H-imidazol-2-yl)-2,6-dialkoxyphenol scaffold.
Stepanek O; Hin N; Thomas AG; Dash RP; Alt J; Rais R; Rojas C; Slusher BS; Tsukamoto T
Eur J Med Chem; 2019 May; 170():276-289. PubMed ID: 30921693
[TBL] [Abstract][Full Text] [Related]
48. A neutral sphingomyelinase resides in sphingolipid-enriched microdomains and is inhibited by the caveolin-scaffolding domain: potential implications in tumour necrosis factor signalling.
Veldman RJ; Maestre N; Aduib OM; Medin JA; Salvayre R; Levade T
Biochem J; 2001 May; 355(Pt 3):859-68. PubMed ID: 11311151
[TBL] [Abstract][Full Text] [Related]
49. Serine protease inhibitors block neutral sphingomyelinase activation, ceramide generation, and apoptosis triggered by daunorubicin.
Mansat V; Bettaïeb A; Levade T; Laurent G; Jaffrézou JP
FASEB J; 1997 Jul; 11(8):695-702. PubMed ID: 9240970
[TBL] [Abstract][Full Text] [Related]
50. Permeability barrier disorder in Niemann-Pick disease: sphingomyelin-ceramide processing required for normal barrier homeostasis.
Schmuth M; Man MQ; Weber F; Gao W; Feingold KR; Fritsch P; Elias PM; Holleran WM
J Invest Dermatol; 2000 Sep; 115(3):459-66. PubMed ID: 10951284
[TBL] [Abstract][Full Text] [Related]
51. Alutenusin, a specific neutral sphingomyelinase inhibitor, produced by Penicillium sp. FO-7436.
Uchida R; Tomoda H; Dong Y; Omura S
J Antibiot (Tokyo); 1999 Jun; 52(6):572-4. PubMed ID: 10470682
[No Abstract] [Full Text] [Related]
52. Ceramide/sphingomyelin cycle involvement in gentamicin-induced cochlear hair cell death.
Chi le NU; Tabuchi K; Nakamagoe M; Nakayama M; Nishimura B; Hara A
Arch Toxicol; 2015 Mar; 89(3):415-21. PubMed ID: 24798086
[TBL] [Abstract][Full Text] [Related]
53. [TNF-induced apoptosis and necrosis in myeloleukemia cells HL-60 is regulated by reactive oxygen metabolites depending on a cell cycle phase].
Martynova EA; Poddubskaia EV; Polosukhina EP; Klimova SV
Biomed Khim; 2003; 49(1):35-45. PubMed ID: 14569872
[TBL] [Abstract][Full Text] [Related]
54. Discovery of N-hydroxy-3-alkoxybenzamides as direct acid sphingomyelinase inhibitors using a ligand-based pharmacophore model.
Yang K; Nong K; Gu Q; Dong J; Wang J
Eur J Med Chem; 2018 May; 151():389-400. PubMed ID: 29649738
[TBL] [Abstract][Full Text] [Related]
55. Total synthesis of (+)-scyphostatin, a potent and specific inhibitor of neutral sphingomyelinase.
Inoue M; Yokota W; Murugesh MG; Izuhara T; Katoh T
Angew Chem Int Ed Engl; 2004 Aug; 43(32):4207-9. PubMed ID: 15307088
[No Abstract] [Full Text] [Related]
56. Inhibition of lipopolysaccharide-induced release of interleukin-8 from intestinal epithelial cells by SMA, a novel inhibitor of sphingomyelinase and its therapeutic effect on dextran sulphate sodium-induced colitis in mice.
Sakata A; Yasuda K; Ochiai T; Shimeno H; Hikishima S; Yokomatsu T; Shibuya S; Soeda S
Cell Immunol; 2007 Jan; 245(1):24-31. PubMed ID: 17466962
[TBL] [Abstract][Full Text] [Related]
57. Inhibition of neutral sphingomyelinase activation and ceramide formation by glutathione in hypoxic PC12 cell death.
Yoshimura S; Banno Y; Nakashima S; Hayashi K; Yamakawa H; Sawada M; Sakai N; Nozawa Y
J Neurochem; 1999 Aug; 73(2):675-83. PubMed ID: 10428064
[TBL] [Abstract][Full Text] [Related]
58. [Synthesis of phosphonic acid and phosphinic acid derivatives for development of biologically active compounds].
Shibuya S
Yakugaku Zasshi; 2004 Nov; 124(11):725-49. PubMed ID: 15516802
[TBL] [Abstract][Full Text] [Related]
59. Phosphatidylinositol-3,5-Bisphosphate is a potent and selective inhibitor of acid sphingomyelinase.
Kölzer M; Arenz C; Ferlinz K; Werth N; Schulze H; Klingenstein R; Sandhoff K
Biol Chem; 2003 Sep; 384(9):1293-8. PubMed ID: 14515991
[TBL] [Abstract][Full Text] [Related]
60. Adsorption of sphingomyelinase of Bacillus cereus onto erythrocyte membranes.
Tomita M; Taguchi R; Ikezawa H
Arch Biochem Biophys; 1983 May; 223(1):202-12. PubMed ID: 6305273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
